BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed) | RFA EY 21 001

FAQs: BRAIN Initiative New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21)

What is this funding opportunity?

This is an NIH discretionary grant opportunity under the BRAIN Initiative titled "New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21)." It supports very early, high-risk ideas intended to transform how researchers record and influence activity in the nervous system.

What is the main scientific goal or driver behind this FOA?

The overarching driver is a core BRAIN Initiative challenge: understanding how electrical and chemical signaling in neural circuits encodes information and produces perception, cognition, emotion, and behavior.

What problem or gap is this program trying to address?

The program is motivated by limitations in current neural interfacing tools. Non-invasive methods often lack spatial or temporal precision and may rely on indirect readouts (for example, blood flow) that do not faithfully reflect underlying neural signals. Invasive methods can capture fundamental biophysical activity at the single-neuron level, but typically only from tens to hundreds of neurons, which is far short of what is needed to understand large-scale circuit dynamics in brains with billions of neurons.

How does this FOA differ from later-stage BRAIN technology opportunities?

This FOA is positioned earlier in the technology pipeline than related BRAIN opportunities that focus on developing or optimizing technologies that are closer to in vivo proof-of-concept. In contrast, this R21 is designed for concepts that may still be untested, preliminary, or even at an initial conceptual stage.

What maturity level of ideas is appropriate for an R21 under this announcement?

Projects can be at a very early stage, including untested concepts or ideas that are still being formulated. The intent is to give investigators room to explore bold directions before animal testing or extensive preliminary datasets are available, with the expectation that successful projects may later mature into more validated platforms suitable for future in vivo development.

What kinds of projects are encouraged?

Projects should emphasize enabling new capabilities for large-scale recording and/or modulation of neural circuit activity. Both experimental and non-experimental work can be supported, as long as the focus is on advancing foundational concepts for recording or modulating nervous system activity at scale.

Are theoretical or computational projects allowed?

Yes. The FOA explicitly allows theoretical and computational efforts such as calculations, simulations, and mathematical or computational modeling. These approaches may be used to argue that a proposed signal source, sensor, readout method, or modulation mechanism is physically and biologically plausible and could meet demanding requirements for recording or manipulating circuit activity in humans or animal models.

What kinds of early experimental validation work are in scope?

The FOA allows practical early validation work that stays short of animal studies. Examples mentioned include building and evaluating prototypes, constructing and testing phantoms, and conducting in vitro or benchtop demonstrations to check fundamental assumptions and reduce risk in the concept.

Does this FOA support animal testing?

The description emphasizes that this opportunity is meant to precede animal testing and extensive preliminary datasets. The focus is on foundational concept development and feasibility work prior to in vivo development.

Are clinical trials supported under this announcement?

No. The opportunity is explicitly not intended for clinical trials, consistent with its focus on early-stage technology concept development rather than testing interventions in people.

What does "recording and modulation" mean in the context of this FOA?

Within the information provided, "recording" refers to methods for measuring neural circuit activity (including the electrical and chemical signaling underlying neural function). "Modulation" refers to methods for influencing or manipulating neural circuit activity. The emphasis is on enabling large-scale capabilities beyond current limits.

Who can apply for this NIH opportunity?

Eligibility is broad across sectors. Eligible applicants include government entities (state, county, city/township, special districts), educational organizations (independent school districts; public/state-controlled and private institutions of higher education), nonprofit organizations (with or without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, public housing authorities/Indian housing authorities, and tribal governments or organizations (including federally recognized tribes and other tribal organizations).

Are minority-serving institutions or community-based organizations eligible?

Yes. The FOA highlights additional eligible groups including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.

Can federal agencies apply?

Yes. Eligible applicants include eligible federal agencies, as listed in the provided eligibility summary.

Can organizations outside the United States apply?

Yes. The FOA includes non-U.S. (foreign) organizations among eligible applicants, based on the provided excerpt.

What is the funding opportunity number and mechanism?

The Funding Opportunity Number is RFA EY 21 001, offered by the National Institutes of Health (NIH), and it uses the R21 grant mechanism.

Which federal activity areas is this opportunity associated with?

It is categorized under broad federal activity areas spanning education, health, income security, and social services, as stated in the source information.

Which CFDA numbers are associated with this opportunity?

The opportunity is associated with multiple CFDA numbers: 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866, 93.867.

What is the key expectation for a competitive proposal under this FOA?

Competitive submissions will typically make a strong case that the idea is genuinely new while still grounded in plausible physics, engineering, and biology; that it addresses a real bottleneck in large-scale neural interfacing; and that it lays out a credible path toward later-stage in vivo testing under future BRAIN-oriented funding opportunities.

What kinds of evidence can be used to establish feasibility at this early stage?

The FOA highlights rigorous theory, modeling, and early prototype or benchtop validation as appropriate ways to establish feasibility, including simulations, calculations, computational modeling, phantom testing, in vitro testing, and prototype evaluation intended to validate fundamental assumptions and de-risk the approach.

Does the provided excerpt specify an award ceiling or the expected number of awards?

No. The provided source excerpt states that it does not specify an award ceiling or an expected number of awards.

What dates are provided for this opportunity?

The source data notes a creation date of 2021-01-15 and an original closing date of 2023-09-21.

What should applicants focus on during the R21 project period for this FOA?

Applicants are encouraged to use the R21 period to establish feasibility for a new direction in neural recording or modulation through rigorous theory, modeling, and early prototype or benchtop validation, with an eye toward eventual maturation into stronger platforms suitable for future in vivo development.